


Figure S4. Impact of intrinsic factors on $C_{\max,ss}$ of gefapixant (**A**) in the Phase 2/3 study population after administration of gefapixant 45 mg BID and (**B**) in stratified RI categories after administration of gefapixant 45 mg BID or 45 mg QD (reference: normal RI with gefapixant 45 mg BID). BID, twice daily; BW, body weight; $C_{\max,ss}$, maximum concentration at steady state; GMR, geometric mean ratio; QD, once daily; RCC, refractory chronic cough; RI, renal impairment; UCC, unexplained chronic cough.

A



B

